- Home
- MBAV vs ZVRA Comparison
MBAV vs ZVRA Comparison
Compare MBAV & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBAV
- ZVRA
- Stock Information
- Founded
- MBAV 2024
- ZVRA 2006
- Country
- MBAV United States
- ZVRA United States
- Employees
- MBAV N/A
- ZVRA N/A
- Industry
- MBAV
- ZVRA Biotechnology: Pharmaceutical Preparations
- Sector
- MBAV
- ZVRA Health Care
- Exchange
- MBAV NYSE
- ZVRA Nasdaq
- Market Cap
- MBAV 413.3M
- ZVRA 400.8M
- IPO Year
- MBAV 2024
- ZVRA 2015
- Fundamental
- Price
- MBAV $13.53
- ZVRA $9.07
- Analyst Decision
- MBAV
- ZVRA Strong Buy
- Analyst Count
- MBAV 0
- ZVRA 8
- Target Price
- MBAV N/A
- ZVRA $22.29
- AVG Volume (30 Days)
- MBAV 702.5K
- ZVRA 551.0K
- Earning Date
- MBAV 01-01-0001
- ZVRA 08-12-2025
- Dividend Yield
- MBAV N/A
- ZVRA N/A
- EPS Growth
- MBAV N/A
- ZVRA N/A
- EPS
- MBAV 0.28
- ZVRA N/A
- Revenue
- MBAV N/A
- ZVRA $40,588,000.00
- Revenue This Year
- MBAV N/A
- ZVRA $292.31
- Revenue Next Year
- MBAV N/A
- ZVRA $78.65
- P/E Ratio
- MBAV $48.81
- ZVRA N/A
- Revenue Growth
- MBAV N/A
- ZVRA 46.47
- 52 Week Low
- MBAV $9.97
- ZVRA $4.20
- 52 Week High
- MBAV $13.73
- ZVRA $9.76
- Technical
- Relative Strength Index (RSI)
- MBAV N/A
- ZVRA 58.37
- Support Level
- MBAV N/A
- ZVRA $8.71
- Resistance Level
- MBAV N/A
- ZVRA $9.37
- Average True Range (ATR)
- MBAV 0.00
- ZVRA 0.33
- MACD
- MBAV 0.00
- ZVRA -0.05
- Stochastic Oscillator
- MBAV 0.00
- ZVRA 50.93
About MBAV M3-BRIGADE ACQUISITION V CORP
M3-Brigade Acquisition V Corp is a blank check company.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.